Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 19

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 19
---
30, 2025, compared to $0 for six months ended
June 30, 2024. The Company recognized $2,939 and $0, respectively, of amortization of debt discount included in interest
expense on the statements of operations for the six months ended June 30, 2025 and 2024. As of June 30, 2025, there was $162,500
in outstanding principal on the June Bridge Note.

Outstanding
Principal on Notes

    Loan Payable
     
    Outstanding
        
        Principal 

    Unamortized
        
        Debt
        Discount

    Outstanding
        
        Principal,
        net of
        
        Debt
Discount 

    May Promissory Note
     
    $
    1,455,416

    $
    —

    $
    1,455,416

    February Bridge Note

    325,000

    (3,733
    )

    321,267

    May Bridge Note

    325,000

    (52,740
    )

    272,260

    June Bridge Note

    162,500

    (38,624
    )

    123,876

    Total As of June 30, 2025
     
    $
    2,267,916

    $
    (95,097
    )
     
    $
    2,172,819

     Loan Payable
     
    Outstanding
        
        Principal

    Unamortized
        
        Debt
        Discount

    Outstanding
        
        Principal,
        net of
         Debt
Discount 

    May Promissory Note
     
    $
    1,455,416

    $
    —

    $
    1,455,416

    Convertible Note

    726,212

    (127,426
    )

    598,786

    Total As of December 31, 2024
     
    $
    2,181,628

    $
    (127,426
    )
     
    $
    2,054,202

14 

NOTE
6 – STOCKHOLDERS’ EQUITY

Initial
Public Offering

On
February 21, 2024, the Company completed its IPO and issued 110,000 shares of Common Stock at a price of $60.00 per
share. The aggregate